According to Zacks, “Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. “
Other equities analysts have also issued reports about the company. HC Wainwright began coverage on Translate Bio in a research note on Monday, December 24th. They set a buy rating and a $21.00 price target on the stock. ValuEngine lowered Translate Bio from a buy rating to a hold rating in a research note on Friday, December 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Translate Bio currently has a consensus rating of Buy and an average price target of $22.75.
Translate Bio (NASDAQ:TBIO) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.09. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $0.80 million. On average, equities analysts forecast that Translate Bio will post -1.52 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in TBIO. Barclays PLC grew its stake in shares of Translate Bio by 82.8% in the 4th quarter. Barclays PLC now owns 6,710 shares of the company’s stock valued at $50,000 after purchasing an additional 3,039 shares during the period. Rhumbline Advisers bought a new stake in shares of Translate Bio in the 4th quarter valued at approximately $77,000. Two Sigma Investments LP bought a new stake in shares of Translate Bio in the 4th quarter valued at approximately $118,000. Teachers Advisors LLC bought a new stake in shares of Translate Bio in the 3rd quarter valued at approximately $126,000. Finally, TIAA CREF Investment Management LLC bought a new stake in shares of Translate Bio in the 3rd quarter valued at approximately $137,000. Institutional investors own 59.27% of the company’s stock.
Translate Bio Company Profile
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Featured Story: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.